

## Changes in the Board of Directors

**Mexico City, May 4, 2020 – Genomma Lab Internacional, S.A.B. de C.V. (BMV: LAB B)** (“Genomma Lab” or “the Company”), one of the leading pharmaceutical and personal care product companies in Mexico with an expanding international presence, informs that by resolution of its Annual General Shareholders’ Meeting held on April 30, 2020, the Company’s Board of Directors is comprised as follows: Rodrigo Alonso Herrera Aspra, Jorge Ricardo Gutiérrez Muñoz, Juan Alonso, Javier Vale Castilla, Ignacio González Rodríguez, Burkhard Wittek, Carlos Javier Alonso Vara, Juan Carlos Gavito Aspe, Marco Francisco Forastieri Muñoz and Sabrina Lucila Herrera Aspra, as Directors, and Ms. Renata Virginia Herrera Aspra as alternate Director of Rodrigo Alonso Herrera Aspra and Sabrina Lucila Herrera Aspra. All of them, except for Mr. Rodrigo Alonso Herrera Aspra and Mr. Burkhard Wittek and Ms. Sabrina Herrera Aspra and Ms. Renata Virginia Herrera Aspra, are Independent Members of the Board of Directors.

In that regard, Mr. Marco Francisco Forastieri Muñoz joined as an Independent Member of the Company’s Board of Directors and Mr. Efraín Tapia Córdova and Rodolfo René Aranda Cobos were appointed as non-members Senior and Alternate Secretary of the Board of Directors of the Company, respectively.

The Shareholders’ Meeting also ratified Mr. Jorge Ricardo Gutiérrez Muñoz as the Company’s Chairman of the Audit and Corporate Practices Committee.

Marco Francisco Forastieri Muñoz. Mr. Forastieri has recently retired from his position as Senior Partner of Ernst & Young (EY), where he held the position of Leader for the Latin America Northern Region. Prior to EY, he founded his own firm: Forastieri Abogados. Francisco has more than 30 years of experience in transactional, corporate, financial and stock market Law both in Mexico and at regional level. Mr. Francisco holds a Degree from *Escuela Libre de Derecho*. He is also secretary of the Board of Directors of other Mexican companies. Francisco served as non-member Secretary of the Company’s Board of Directors until February 2020.

---

### About Genomma Lab Internacional

Genomma Lab Internacional, S.A.B. de C.V. is one of the fastest growing pharmaceutical and personal care products companies in Latin America. Genomma Lab develops, sells and markets a broad range of Premium branded products, many of which are leaders in the categories in which they compete in terms of sales and market share. The Company has a sound business model through a unique combination of a new product development process, consumer oriented marketing, a broad retail distribution network and a low-cost, highly flexible supply chain operating model. For more information visit: [www.genommalab.com](http://www.genommalab.com)

Genomma Lab’s shares are listed on the Mexican Stock Exchange under the ticker “**LABB**” (**Bloomberg: LABB:MM**).

### Note on Forward-Looking Statements

This report may contain certain forward-looking statements and information relating to the Company that reflect the current views and/or expectations of the Company and its management with respect to its performance, business and future events. Forward looking statements include, without limitation, any statement that may predict, forecast, indicate or imply future results, performance or achievements, and may contain words like “believe,” “anticipate,” “expect,” “envisages,” “will likely result,” or any other words or phrases of similar meaning. Such statements are subject to a number of risks, uncertainties and assumptions. We caution you that a number of important factors could cause actual results to differ materially from the plans, objectives, expectations, estimates and intentions expressed in this presentation and in oral statements made by authorized officers of the Company. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of their dates. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

### Mexico:

Enrique González Casillas +52 (55) 5081 0075  
[inversion@genommalab.com](mailto:inversion@genommalab.com)

### USA:

Bárbara Cano +1 (646) 452 2334  
[barbara@inspigroup.com](mailto:barbara@inspigroup.com)